[Form 4] THERMO FISHER SCIENTIFIC INC. Insider Trading Activity

Rhea-AI Filing Summary

Thermo Fisher Scientific (TMO) reported insider transactions by an Executive Vice President on 11/10/2025 under a Rule 10b5-1 trading plan. The officer exercised 725 options at $253.99 and 2,250 options at $294.02, then sold 725 shares and 2,250 shares at $580.

Following these transactions, the officer beneficially owned 21,152.223 shares of common stock, held directly. The options exercised were previously granted and had vested in four equal annual installments ending in 2023.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pettiti Gianluca

(Last) (First) (Middle)

168 THIRD AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025		M		725	A	$253.99	21,877.223	D
Common Stock	11/10/2025		S(1)		725	D	$580	21,152.223	D
Common Stock	11/10/2025		M		2,250	A	$294.02	23,402.223	D
Common Stock	11/10/2025		S(1)		2,250	D	$580	21,152.223	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$253.99	11/10/2025		M			725	(2)	02/26/2026	Common Stock	725	$0	0	D
Stock Option (Right to Buy)	$294.02	11/10/2025		M			2,250	(3)	09/05/2026	Common Stock	2,250	$0	0	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 10, 2025.

2. The option vested in four equal installments on February 26, 2020, 2021, 2022 and 2023.

3. The option vested in four equal installments on September 5, 2020, 2021, 2022, and 2023.

	/s/ Melodie T. Morin, Attorney-in-Fact for Gianluca Pettiti	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did TMO disclose?

An Executive Vice President exercised options and sold shares on 11/10/2025 pursuant to a Rule 10b5-1 plan.

How many Thermo Fisher (TMO) options were exercised?

The officer exercised 725 options at $253.99 and 2,250 options at $294.02.

How many TMO shares were sold and at what price?

The officer sold 725 shares and 2,250 shares at $580 per share.

What are the officer’s TMO holdings after the transactions?

Beneficial ownership was 21,152.223 shares, held directly, after the reported trades.

Were the sales under a 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on February 10, 2025.

When did the exercised options vest?

The options vested in four equal installments ending on 02/26/2023 and 09/05/2023, respectively.